Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (3MB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-530922
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.53092
Zusammenfassung
Immune checkpoint inhibitors have revolutionized treatment of advanced melanoma, but commonly cause serious immune-mediated complications. The clinical ambition of reserving more aggressive therapies for patients least likely to experience immune-related adverse events (irAE) has driven an extensive search for predictive biomarkers. Here, we externally validate the performance of 59 previously ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags